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Abstract
The aim of the present study was to identify influenza A-derived peptides which bind to both
HLA class I and -II molecules and by immunization lead to both HLA class I and class II
restricted immune responses. Eight influenza A-derived 9-11mer peptides with simulta-
neous binding to both HLA-A*02:01 and HLA-DRB1*01:01 molecules were identified by
bioinformatics and biochemical technology. Immunization of transgenic HLA-A*02:01/HLA-
DRB1*01:01 mice with four of these double binding peptides gave rise to both HLA class I
and class II restricted responses by CD8 and CD4 T cells, respectively, whereas four of the
double binding peptides did result in HLA-A*02:01 restricted responses only. According to
their cytokine profile, the CD4 T cell responses were of the Th2 type. In influenza infected
mice, we were unable to detect natural processing in vivo of the double restricted peptides
and in line with this, peptide vaccination did not decrease virus titres in the lungs of intrana-
sally influenza challenged mice. Our data show that HLA class I and class II double binding
peptides can be identified by bioinformatics and biochemical technology. By immunization,
double binding peptides can give rise to both HLA class I and class I restricted responses, a
quality which might be of potential interest for peptide-based vaccine development.
Introduction
HLA class I and II molecules are of importance for influenza virus processing and clearance. In
primary influenza infections, cytotoxic, influenza-specific CD8 T cells are important for termi-
nating the acute infection and they also contribute to long-term immunity [1,2]. CD4+ T cells
may, in addition to their B cell supporting role in humoral immunity, act as direct effectors in
protection against influenza and generate memory immunity [3].
We have previously identified 34 new HLA-class I binding influenza A-derived antigenic
9-mer peptides, which collectively bind to the twelve HLA class I supertypes [4,5], thus globally
covering HLA by> 99%. Surprisingly, eighteen of these peptides gave rise exclusively to HLA
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class II restricted responses when assayed in ELISpot cultures using PBMC from immune
donors ([2] and unpublished data). Similarly, 50% of PBMC from donors immunized with vac-
cinia virus and 100% of BCG vaccinated donors gave rise to HLA class II restricted responses
when tested against HLA class I binding 9-mer peptides in IFNγ ELISpot assays [6,7].
We have speculated on the mechanisms behind presentation of such double restricted pep-
tide epitopes, including the likelihood of autophagy and cross presentation or transmission of
peptides from unstable HLA class I to class II molecules on the cell surface [8]. Functionally,
immunization with peptides restricted by both HLA class I and II molecules might, due to
increased peptide specific T helper activity, lead to higher levels of peptide specific CTL immu-
nity in comparison with peptides restricted only by HLA class I molecules. The aim of the pres-
ent study was to evaluate the immunogenicity of double restricted influenza-derived 9-11mer
peptides in HLA-A02:01/HLA-DRB101:01 transgenic mice. The HLA class I/II composition
of our transgenic mouse model appears to be well warranted for studying the immunogenicity
of double restricted influenza epitopes, first, because 50% and 20% of the European population
carry the HLA-A02:01 and the HLA-DRB101:01 allele, respectively [www.allelefrequencies.
net], and secondly, because many CD8 T cell responses in influenza A virus infections appear
to be restricted by the HLA-A02:01 allele [9]. Furthermore, we also studied the protective
effect of peptide immunization in mice challenged intranasally (i.n.) with influenza A virus.
Materials and Methods
Mice and Ethics
HLA-A02:01/HLA-DRB101:01 transgenic H-2 class I-/class II-knockout mice on a C57BL/6
background were purchased from the Pasteur Institute, Paris, France [10]. Transgenic mice
were bred and maintained in the animal facility of the Panum Institute, University of Copenha-
gen, Denmark, and all mice were at least 7 weeks old before entering into experiments. Mice
were housed under controlled microbial conditions. Experiments were conducted in accor-
dance with national Danish guidelines (Amendment # 1306 of November 23, 2007) regarding
animal experiments as approved by the Danish Animal Experiments Inspectorate, Ministry of
Justice, permission number 2009/561-1679.
Bioinformatics search strategy for CTL and Th epitopes derived from
influenza A virus
Epitope predictions were performed on the basis of datasets obtained from the Influenza
Sequence Database (www.flu.land.gov). Only peptides from influenza A-derived constant pro-
teins such as M1, M2, NS1, PB1, PB2, PA and NP proteins were included in the analysis, while
the variable proteins N and H were excluded. Bioinformatic analyses were used to identify dou-
ble binding influenza A-derived peptides, i.e. peptides predicted to bind to both HLA-A02:01
and to HLA-DRB101:01. Binding to HLA-A02:01 was performed using NetMHCpan-2.8
[11,12]. Binding to HLA-DRB101:01 was performed using NetMHCIIpan-3.0 [13,14] and
both prediction methods are available at www.cbs.dtu.dk/services. Analyses were performed
using the Influenza strain A/Puerto Rico/8/1934(H1N1) [Refseq accession numbers:
NP_040978.1,NP_040979.2,NP_040980.1,NP_040981.1,NP_040982.1,NP_040983.1,
NP_040984.1,NP_040985.1,NP_040986.1,NP_040987.1].
Peptides were selected based on the following strategy. First peptides of length 9–11 amino
acids with predicted binding to HLA-A02:01 stronger than 50nM were selected. Next this list
was filtered to include only peptides that either were predicted to bind HLA-DRB101:01 or
were part of a 15mer peptides that was predicted to bind HLA-DRB101:01 with an affinity
HLA Double Restricted Peptides
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stronger than rank 10% (the IEDB recommended threshold for MHC class II peptide binding
classification). Finally, the selection was extended by a peptide that is part of a 15mer with very
strong binding to HLA-DRB101:01 even though it lacked binding to HLA-A02:01, and a
peptide with strong binding to HLA-A02:01 even though it lacked binding to
HLA-DRB101:01 (details on the peptide selection and predicted binding values are given
Table 1). These peptides were all present in the influenza strain A/Puerto Rico/8/34 H1N1
used for the challenge of mice.
Table 1. Peptides predicted andmeasured for binding to HLA-A*02:01 and HLA-DRB1*01:01.
Protein Peptide sequence Response HLA-A*02:01 HLA-DRB1*01:01 HLA-DRB1*01:01 15mer
Measured
nM
Predicted
nM
Measured
nM
Predicted
%rank
Peptide sequence Predicted
%rank
PA(282–
292)
FLLMDALKLSI I/II* 24 15.63 23 0.05
PB1(410–
419)
GMFNMLSTVL I/II 384 35.1 29 5
PA(282–
290)
FLLMDALKL I/II 14 15.42 46 0.1
PB1(408–
418)
MMGMFNMLSTV I/- 51 10.59 172 5
PB1(318–
326)
FLAMITYMT I/- 253 17.03 557 1.5
NS2(99–
107)
FMQALHLLL I/- 13 9.74 >5000 5
NP(258–
266)
FLARSALIL -/- 0.9 61.5 97 8
PB2(49–57) WMMAMKYPI -/- 36 3.75 >5000 7
PB2(49–59) WMMAMKYPITA -/- 75 12.31 528 3
M(41–51) VLMEWLKTRPI -/- 101 9.71 119 9
PB1(407–
417)
MMMGMFNMLST -/- 36 27.25 315 5
PB1(217–
227)
YLIRALTLNTM -/- 46 28.42 76 1.5
NP(297–
306)
SLVGIDPFRL -/- 70 43.31 460 6
PB1(410–
418)
GMFNMLSTV I/II 23 6.85 34 32 GMFNMLSTVLGVS 2
NS1(128–
136)
IILKANFSV I/- 45 19.35 >5000 15 KNIILKANFSVIF 3
M(134–142) RMGAVTTEV I/- 133 28.24 >5000 50 LIYNRMGAVTTEV 0.8
M(58–66) GILGFVFTL I***/- 3 15.03 >5000 50 GILGFVFTLTVPSER 5
PB1(413–
421)
NMLSTVLGV -/- 16 9.4 >5000 32 GMFNMLSTVLGVS 2
NP(306–
315)
LLQNSQVYS (I)/- 1369 3168.34 >5000 50 PFRLLQNSQVYSL 0.1
PB1(166–
174)
FLKDVMESM I**/- 51 23.43 >5000 32
Reference
peptide
YKYVKQNTLKLATHHHHHH - 8
*Type of immune response: I, CD8 response; II, CD4 response; -,no response (conf. Fig 1)
**Known HLA-A*02:01 binding and processable inﬂuenza peptide [21].
***Measured by FACS (conf. Table 2).
doi:10.1371/journal.pone.0145629.t001
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Peptides
The peptides were synthesized at Schafer N, Copenhagen, Denmark or at Zhengzhou Peptides
Pharmaceutical technology Co., Ltd. Zhengzhou City, Henan Province P.R China by standard
9-fluorenylmethyloxycarbonyl (FMOC) chemistry, and purified by reversed-phase high-per-
formance liquid chromatography (at least 80%, usually>95% purity) and validated by mass
spectrometry (Shafer-N, Copenhagen, Denmark). Peptides were dissolved before each
experiment.
Biochemical peptide-HLA-I and–II binding assays
The biochemical assay for peptide–MHC-I binding was performed as previously described
[15,16]. Briefly, denatured and purified recombinant HLA heavy chains were diluted into a
renaturation buffer containing β2-microglobulin and graded concentrations of the test pep-
tide, and incubated at 18°C for 48h allowing equilibrium to be reached. We have previously
demonstrated that denatured HLA molecules can de novo fold efficiently, however, only in
the presence of appropriate peptide [12]. The concentration of peptide–HLA complexes
generated was measured using Luminescent Oxygen Channeling Immunoassay (LOCI)
and plotted against the concentration of peptide offered. Because the effective concentra-
tion of HLA (in casu 0.5nM) used in these assays is below the equilibrium dissociation con-
stant (KD) of most high-affinity peptide–HLA interactions, the peptide concentration
leading to half-saturation of the HLA is a reasonable approximation of the affinity of the
interaction.
Affinity measurements of peptides to recombinant HLA-DRA01:01/DRB101:01 mole-
cules were done according to previous work with minor modifications [17]. Briefly, pep-
tides including a reference peptide, known to bind to HLA-II DR (HA 308–318,
YKYVKQNTLKLAT) [18], were dissolved and titrated in 25% glycerol, 0.1% pluriol (F68),
PBS. An HLA-II stock solution consisting of bacterially expressed and urea denatured alpha
and beta chains at appropriate concentrations was diluted into refolding buffer (100 mM
Tris/Citrate, 25% Glycerol, 0.01% Pluriol, pH 7). The diluted HLA-II stock was subse-
quently mixed 1:1 with peptide titrations and incubated at 18°C for 48h. Formed HLA-II
complexes were detected using a homogenous proximity assay (Alphascreen, Perkin Elmer,
USA), briefly streptavidin coated donor beads and in-house L243 (murine monoclonal
anti-DR) conjugated acceptor beads, both 5 mg/ml, were diluted into PBS 0.1% Pluriol F68
and added to the HLA-II complexes giving a final concentration of 5μg/ml of each. Follow-
ing 18h of incubation at 18°C they were read on an EnVision Reader (Perkin Elmer, USA)
and analyzed according to [17].
Immunization of mice
Peptides were dissolved and mixed with Freund’s Incomplete Adjuvant (FIA) (Sigma, USA),
Freund’s Complete Adjuvant (FCA) or CAF09 (Statens Serum Institute, Denmark). CAF09 is a
novel cationic liposomal adjuvant formulation comprised of DDA (dimethyldioctadecylammo-
nium, 250 μg/dose) liposomes combined with MMG-1 (monomycoloyl glycerol 1, 50 μg/dose)
and Poly(I:C) (50 μg/dose) [19]. Mice were immunized two or three times with either 20 or 50
nmol peptide at two week intervals. When using Freunds’s Adjuvants, peptides were dissolved
in PBS, mixed with equal amounts of adjuvant and 100 μl were administered subcutaneously
(s.c.). Peptides given with CAF09 were dissolved in 10 mM Tris-buffer, mixed with equal
amounts of CAF09 and injected intraperitoneally (i.p.) in 200 μl.
HLA Double Restricted Peptides
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ELISpot assay
96 well Multiscreen HTS ELISpot plates (Millipore, Germany) were coated overnight at 4°C
with unlabeled anti-mouse Ab purchased at BD Bioscience, USA (3 μg/ml for anti-IFNγ or
5 μg/ml for anti-IL-4). The next day, plates were washed 6 times with blocking solution (RPMI
1640 supplemented with 10% FBS and 1% penicillin, streptomycin and L-glutamine). 200 μl
blocking solution was added and plates incubated for at least 2h at room temperature. Cells
were prepared by pressing spleens trough a fine steel mesh, and splenocytes from all mice in a
group were subsequently pooled. Cells were then added to wells (2x105 cells/well for IFNγ
assays and 1x106 cells/well for IL-4 assays) and peptides were added in a final concentration of
20 nmol/ml. For non-depleted samples, 2x105 or 1x106 cells/well were added directly from the
pooled cell population. For CD4 or CD8 depleted samples, a fraction of the pooled cells was
first depleted for CD4+ or CD8+ cells (described in detail below) before 2x105 or 1x106 of the
depleted cells were added to wells. Each sample was run in four replicates. Concanavalin A
(ConA) stimulated cells (3 μg/ml) were included as a positive control and unstimulated cells
were used as a negative control. Plates were incubated for 18-22h for IFNγ assays and 40-44h
for IL-4 assays at 37°C and 5% CO2. Plates were washed twice with Milli Q H2O, allowing wells
to soak 3–5 min at each step. Next, plates were washed four times with washing buffer (PBS
containing 0.005% Tween 20), letting wells soak for 1–2 min at each step. Biotinylated Ab (BD
Biosciences, USA) was diluted in PBS with 1% BSA to a final concentration of 1.2 μg/ml (anti-
IFNγ) or 2 μg/ml (anti-IL-4) and 100 μl was added to wells. Plates incubated at room tempera-
ture for 2h. Plates were then washed 6 times with washing buffer, while allowing wells to soak
1–2 min at each washing step. HRP Streptavidin (BD Bioscience, USA) was diluted 1:100 in
PBS with 10% FBS and 100 μl was added to each well. Plates incubated for 1h at room tempera-
ture. HRP Streptavidin was discarded and the protective plastic bottom was removed from the
plates. Next, wells were washed 6 times with washing buffer and twice with PBS, allowing plates
to soak for 1–2 min at each step. 100 μl of EAC substrate reagent set (BD Bioscience, USA) was
next added to each well and spots were allowed to develop (30–60 sec). The AEC was discarded
appropriately and the reaction was stopped by the addition of Milli Q H2O to the wells. Finally,
plates were washed 6 times with Milli Q H2O and dried at room temperature in the dark for 1
or more days before spot forming units were counted using a CTL-Immunospot S6 Macro
Analyzer (CTL, Germany).
Spleen cell preparation and intracellular cytokine measurements
Spleens were isolated and single cell suspensions were obtained by pressing the organs trough a
fine steel mesh; subsequent staining for flow cytometry was performed as previously described
[20]. For intracellular staining, 2x106 splenocytes were re-suspended in supplemented RPMI
1640 and stimulated ex vivo with relevant peptides in the presence of IL-2 (50 IU/ml) and mon-
ensin (2 μg/ml; to block Golgi vesicle transport). Control cultures did not receive any peptide.
After 5 hours of stimulation, cells were stained for cell surface markers, followed by permeabili-
zation and intracellular staining as described [20]. Cells were analyzed using a FACS Calibur
(BD Biosciences, USA). At least 104 mononuclear cells were gated using a combination of side
and forward scatter to exclude dead cells and debris. Data analysis was conducted using FlowJo
(Tree Star, USA). The gating strategy for FACS analysis is shown in the supplementary mate-
rial, S1 Fig.
CD8+ and CD4+ T cell depletion
Spleens, bronchoalveolar fluids and mediastinal lymph nodes were isolated and single cell sus-
pensions were obtained by pressing the organs trough a fine steel mesh. Cells were mixed with
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either rat anti-CD4 or anti-CD8 Ab (clone YTS191 or YTS169, a kind gift by Steven Cobbold,
University of Oxford) and left on ice for 30 min. Sheep anti-Rat IgG Dynabeads (Life Technol-
ogies, USA) (100μl/2x107 cells) were washed and used for depletion. After cells had incubated
with Ab for 30 min, they were washed twice with 5 ml RPMI supplemented with 10% FBS, 1%
L-glutamine, penicillin and streptomycin, as well as 2-ME (5x10-5 Mol). Cells were resus-
pended in 5 ml supplemented RPMI and Dynabeads were added. Tubes were placed in an end-
over-end shaker for 40 min at 4°C. Finally, tubes were placed on a magnet and depleted cell
suspensions were isolated and washed once in supplemented in RPMI before being added to
the ELISpot plates. As a control, surface staining for CD8 and CD4 was completed after each
experiment using flow cytometry to ensure that depletion had been satisfactory. The results of
a representative cell depletion experiment are shown in the supplementary material, S2 Fig.
Antibodies for flow cytometry
The following mAb were used as rat anti-mouse antibodies: PerCP-Cy5.5-conjungated anti-
CD8, FITC-conjungated anti-CD44, PE-conjungated anti-CD4, APC-conjungated anti-IFNγ
(Nordic Biosite, Sweden).
Influenza strains and influenza challenge
For evaluation of clinical relevance, mice were challenged with Influenza A/Puerto Rico/8/34
(H1N1). Briefly, the mice were anaesthetized by i.p. injection of 300–500 μl of Avertin (25 mg/
ml) and infected i.n. with graded doses of virus and the LD50 was estimated. The weight of the
mice was monitored daily and mice suffering from a weight loss greater than 25% of their start-
ing weight were sacrificed for humane reasons. In challenge experiments, mice were immu-
nized i.p. three times and then challenged with 4, 0.4 or 0.04 LD50 of influenza one week after
the final immunization. Lungs were then isolated 5 days post infection and snap frozen in liq-
uid nitrogen. Subsequently, lungs were stored at -80°C before being tested for levels of virus by
Q-PCR (see below). For peptide response experiments, mice were challenged with 4 LD50 or
0.4 LD50 of influenza and 10 days later, spleens, bronchoalveolar fluids, and mediastinal lymph
nodes were collected and tested for peptide reactivity in IFNγ ELISpot or intracellular FACS
staining.
RNA purification
Mice were euthanized and lungs were isolated and immediately snap frozen in liquid nitrogen.
Total RNA was extracted using an RNeasy midi kit (Qiagen, Hilden, Germany) as described by
the manufacturer. Briefly, lungs were homogenized in a lysis buffer using a homogenizer (Bie
& Berntsen, Denmark), cell suspensions were centrifuged and supernatants were isolated and
mixed with 70% ethanol. Lysates were added to RNeasy midi spin columns and spun, to bind
the RNA to the filters. After several washing steps, total RNA was eluted from the column by
the addition of RNase free water. Finally, the total RNA concentration and purity was mea-
sured using a NanoDrop 2000c Spectrophotometer (Thermo Fischer Scientific, USA) and the
associated computer program NanoDrop 2000.
Quantitative real time polymerase chain reaction (Q-PCR)
One-step duplex Q-PCR was performed with 0.1 μg total RNAper sample using a 1-step Bril-
lant II Q-RT-PCR Master Kit (Stratagene, USA). The Q-PCR program was: 30 min/50°C, 10
min/95°C; followed by 40 cycles of 30 sec/95°C, 1 min/58°C, and 30 sec/72°C. The following
primers and probes were used: M probe: 5’ FAM—TCA GGC CCC CTC AAA GCC GA—
HLA Double Restricted Peptides
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BHQ ‐ 1 3’, M forward primer: 5’ AGA TGA GTC TTC TAA CCG AGG TCG 3’, M reverse
primer: 5’ TGC AAA AAC ATC TTC AAG TCT CTG 3’, GAPDH probe: 5’HEX—CGC CTG
GAG AAA CCT GCC AAG TAT—BHQ – 1 3’, GAPDH forward primer: 5’ CAA TGT GTC
CGT CGT GGA 3’, GAPDH reverse primer: 5’ GAT GCC TGC TTC ACC ACC 3’. Each sam-
ple was run in triplicates and a no template control was added in duplicates to detect any possi-
ble background signals. To evaluate the efficiency of the amplification, a -10x sample titration
series was added in duplicates. Also, a -10x plasmid titration series of a paCCMV plasmid
encoding the coding region of the influenza M gene was added in duplicates. This plasmid
titration curve was used for absolute quantifications of the total number of copies of the influ-
enza M gene in the organ samples. The Q-PCR data analysis was performed on a Mx3005P
Real-time Q-PCR instrument, and the results were analysed using the software programme
MxPro–Mx3005p v. 4.1 (Stratagene, USA).
Statistical analysis
Quantitative results were compared using the Mann–Whitney U test, and p values< 0.05 were
considered statistically significant.
Results
Prediction and biochemical validation of 9-11mer influenza epitopes
binding to HLA-A*02:01 and HLA-DRB1*01:01
Initially, we were interested in identifying 9-11mer epitopes from conserved proteins (M1, M2,
NS1, PB1, PB2, PA and NP proteins) derived from the H1N1 influenza strain A/Puerto Rico/8/
34 capable of binding to both HLA-A02:01 and HLA-DRB101:01. Epitope predictions were
performed (see M&M section) and nineteen 9-11mer peptides predicted to bind to
HLA-DRB101:01 and/or HLA-A02:01 were identified. These peptides were synthesized and
tested for binding to recombinant HLA-A02:01 and HLA-DRB101:01 molecules in a bio-
chemical system (see M&M section). Table 1 shows the results of these binding assays. The
overall agreement between the predicted and measured binding values is high. 15 peptides
were measured to bind to HLA-A02:01 with high affinity (KD< 100 nM), and only one pep-
tide (the one that lacked predicted binding) failed to bind HLA-A02:01.Eight of the peptides
were measured to bind to HLA-DRB101:01 with a KD value below 200 nM. These all corre-
sponded to peptides with a predicted rank< 10% (the IEDB recommended threshold for
MHC class II peptide binding classification). Only one of the peptides selected as nested bind-
ers within a 15mer peptide showed binding to DRB101:01, which is in general accordance
with the predicted binding values. Seven of the HLA-DRB101:01 binding peptides also
showed high affinity for HLA-A02:01. Thus, it appears that a significant number of 9-11mer
influenza-derived peptides can bind simultaneously to both HLA class I and II molecules.
Table 1 includes a HLA-DRB101:01 19mer reference peptide [18] and the known
HLA-A02:01 binding influenza matrix M(58–66) peptide [21].
The immunogenic properties of these double binding peptides were further tested in a
transgenic mouse model.
Cationic adjuvant formulation 09 (CAF09) induces strong T cell
responses
To investigate the in vivo immunogenicity of the peptides depicted in Table 1, we had to
determine an appropriate immunization platform. Since Freund’s adjuvants have been
widely used for peptide immunization in the literature, including studies done with influenza
HLA Double Restricted Peptides
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peptides in our group, we considered it a possible candidate. Table 2 includes immunization
data obtained from 13 groups of 2–3 mice each. Initially, we determined the percentage of
IFNγ producing splenic CD8 and CD4 T cells from HLA transgenic mice immunized s.c. at
different time points, with different combinations of FCA or FIA, and in combination with
different amounts of influenza peptide PA (282–290), PB1(410–418) and NS1(128–136).
These peptides showed strong to intermediate binding affinities for both class I and II mole-
cules (Table 1). The known HLA-A2 binding and processable peptide M(58–66) [21] was
included as a positive control for a HLA-A2 restricted response. Intracellular staining
revealed that no marked IFNγ production was detected from either CD8 or CD4 T cells
when immunizing with FCA and/or FIA. A minor CD8 T cell response was, however,
detected for NS1(128–136) and M(55–66) in two different setups. On the other hand, when
immunizing HLA transgenic mice i.p. with peptides combined with the recently developed
cationic liposome adjuvant CAF09 (15), high levels of IFNγ was produced by CD8 T cells
specific for influenza peptides PA(282–290), PB1(410–418) as well as M(58–66). Thus, three
biweekly injections with 20 nmol peptide and CAF09 as an adjuvant were therefore used as
an immunization platform for the remainder of the study.
Table 2. FACS analysis of splenic T cells*.
Adjuvant Immunization peptide(s) Amount of
peptide
Days of
immun.
Peptide for
stimulation
% IFNγ prod.CD8
cells
% IFNγ prod.CD4
cells
FCA/FIA PB1(166–174) + NS1
(128136)
20 nmol 0 and 14 PB1(166–174) 0.037 ± 0.035 0
FCA/FIA PB1(166–174) + NS1(128–
136)
20 nmol 0 and 14 NS1(128–136) 1.267 ± 1.462 0
FIA PB1(166–174) + NS1(128–
136)
50 nmol 0 and 14 PB1(166–174) 0 0.003 ± 0.003
FIA PB1(166–174) + NS1(128–
136)
50 nmol 0 and 14 NS1(128–136) 0.211 ± 0.082 0.007 ± 0.008
FIA PB1(166–174) + NS1(128–
136)
50 nmol 0 and 21 PB1(166–174) 0.003 ± 0.006 0.003 ± 0.006
FIA PB1(166–174) + NS1(128–
136)
50 nmol 0 and 21 NS1(128–136) 0.200 ± 0.157 0.007 ± 0.006
FIA PA(282–290) 20 nmol 0 and 14 PA(282–290) 0.270 ± 0.311 0
FIA M(58–66) 20 nmol 0 and 14 M(58–66) 0.285 ± 0.361 0
FIA PA(282–290) 20 nmol 0, 14 and 28 PA(282–290) 0.447 ± 0.285 0.07 ± 0.012
FIA PB1(410–418) 20 nmol 0, 14 and 28 PB1(410–418) 0.643 ± 0.860 0.003 ± 0.006
FIA NP(258–266) 20 nmol 0, 14 and 28 NP(258–266) 0.017 ± 0.029 0
FIA M(58–66) 20 nmol 0, 14 and 28 M(58–66) 2.487 ± 0.496 0.003 ± 0.006
CAF09 PA(282–290) 20 nmol 0, 14 and 28 PA(282–290) 14.457 ± 6.160 0.440 ± 0.442
CAF09 PB1(410–418) 20 nmol 0, 14 and 28 PB1(410–418) 18.557 ± 13.515 0.013 ± 0.015
CAF09 NP(258–266) 20 nmol 0, 14 and 28 NP(258–266) 0.040 ± 0.061 0.007 ± 0.006
CAF09 M(58–66) 20 nmol 0, 14 and 28 M(58–66) 15.157 ± 1.,019 0.023 ± 0.040
* Subcutaneous and intraperitoneal immunization approaches with different HLA-A*02:01 and DRB1*01:01 binding peptides in HLA transgenic mice
(n = 2–3). Each mouse was evaluated individually by intracellular IFNγ staining and FACS analysis of splenic T cells and cells analyzed were gated as
CD8+IFNγ+ or CD4+IFNγ+. All immunizations using Freund’s adjuvants (FCA or FIA) were given subcutaneously, while CAF09 was administered by
intraperitoneal injections. The experiments were conducted once.
doi:10.1371/journal.pone.0145629.t002
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Four influenza A-derived epitopes show HLA class I/II double restricted
responses in IFNγ ELISpot measurements
Having decided on an immunization approach, we next investigated which, if any, of the pre-
dicted and validated influenza A epitopes shown in Table 1 could in fact induce HLA-I and–II
double restricted T cell responses. Hence, we immunized 72 transgenic mice in groups of 3–5
animals with the individual 9-11mer peptides and CAF09 as adjuvant and examined the epi-
tope-specific T cell responses one week after the last immunization. Mice immunized with M
(58–66) were included in all experiments as a positive control. Mice immunized with M(58–
66) were included in all experiments as a positive control. Since preliminary results had found
ELISpot assay to display more than 10 times higher sensitivity and a lower background than
intracellular IFNγ staining and FACS analysis (S1 Fig), we now used this technology to deter-
mine responses in unfractionated T lymphocytes and cells depleted for CD8 or CD4 positive
cells. Fig 1 shows the immunization data which are also summarized in Table 1 (left column).
We examined a total of 19 peptides and observed 8 peptides, including four HLA-A02:01/
DRB101:01 double bindings ones, which were not immunogenic at all. Seven epitopes were
found to be exclusively HLA-A02:01 restricted, including the known HLA-A02:01 epitope M
(58–66) [21] whereas no peptide appeared to be only HLA-DRB101:01 restricted. Finally and
most important, four 9-11mer peptides; PA(282–290), PA(282–292), PB(410–418) and PB1
(410–419), were observed to elicit both CD8 and CD4 T cell responses.
To examine if the double restricted responses primarily induces a Th1 or Th2 response, we
looked into the expression of the Th2 cytokine IL-4 as well as the Th1 cytokine IFNγ after
immunization of individual mice with the four double restricted peptides and M(58–66). As
shown in Fig 2, T cells depleted of CD8 cells showed high levels of IL-4 secretion and low levels
of IFNγ production indicating their Th2 nature, whereas CD4 depleted cell populations as
expected showed high levels of IFNγ production typically for activated CTLs. As expected,
immunization with the HLA-A02:01 restricted peptide M(58–66) [17]only gave rise to a CTL
response. These results show that immunization with three of the four double restricted epi-
topes found in this study will induce both CTL and Th2 reactivity.
Fig 1. Induction of double restricted responses after peptide immunization of HLA transgenic mice.
Eighteen groups of 3–5 mice were injected intraperitoneally three times at two week intervals with CAF09
plus one of the 9-11mer peptides (20nM). One week after the last immunization, IFNγ ELISpot was used to
measure HLA-A*02:01 and/or HLA-DRB1*01:01 restricted CD8 and CD4 T cell responses. As a control, a
group of mice (n = 4) was injected intraperitoneally three times at two week intervals with CAF09 plus the
known HLA-A*02:01 binding peptide M(58–66) (21). Each bar represents mean ± SD of IFNγ spot forming
units (SFU) of groups of 3–5 immunized mice from which splenocytes were pooled and depleted for CD4 or
CD8 positive cells before being stimulated ex vivowith peptide in four replicate cultures. Experiments were
conducted 1–5 times depending on the individual peptides.
doi:10.1371/journal.pone.0145629.g001
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Lack of natural responses against the influenza-derived peptides
In order to determine if the peptides used in this study, including the four immunogenic, dou-
ble restricted epitopes, are processed and presented to the immune system during natural infec-
tion, we next investigated peptide specific responses in influenza (PR8) challenged HLA
transgenic mice. Fig 3 shows data from individual influenza challenge experiments (2–5 mice
per experiment) in which splenic T cells from influenza PR8 infected mice were tested in IFN-
γELISpot for recognition of the influenza peptides depicted in Table 1 and Fig 1. Included is
the known HLA-A02:01 binding M(58–66) peptide [21] as a known positive control. As
shown in Fig 3, reactivity was only observed against peptide M(58–66), suggesting that only
this peptide is naturally processed during viral infection. Furthermore, this lack of response
against epitopes, of which the majority was predicted and measured to bind to HLA-A02:01
with high affinity, was also evident in T cells isolated from both bronchoalveolar lavage fluids
and mediastinal lymph nodes from influenza challenged mice (data not shown).
Fig 2. Immunization with the four double restricted epitopes induces both CTL and Th2 reactivity. Five
groups of HLA transgenic mice were immunized intraperitoneally three times at two week intervals with
CAF09 plus one of the four double restricted peptides or M(58–66) (20nM) [21]. One week after last
immunization, IFNγ (A) or IL-4 (B) ELISpot was used to measure spot forming units (SFU) from splenocytes.
Cells were pooled from each group and depleted for CD4 or CD8 positive cells before being stimulated ex
vivowith peptide in four replicate cultures. Each bar represents mean ± SD of IFNγ (A) or IL-4 (B) spot
forming units (SFU) of groups of 4 immunized mice. Experiments were conducted twice.
doi:10.1371/journal.pone.0145629.g002
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Fig 3. Influenza infected HLA transgenicmice show no reactivity towards any of the immunogenic
peptides. HLA transgenic mice were challenged intranasally with 4 LD50 (B) or 0.4 LD50 (A and C) of
influenza A. IFNγ production from splenocytes was detected 10 days later using IFNγ ELISpot (A and B) or
flow cytometry (C). In A and B, each bar represents mean ± SD of IFNγ spot forming units (SFU) of groups of
4–5 mice from which splenocytes were pooled before being stimulated ex vivo with peptide in four replicate
cultures. In C, each bar represents mean ± SD of the number of IFNγ producing splenic CD8 T cells from 2
individual mice after ex vivo stimulation with peptide. Experiments were conducted 1–4 times depending of
the peptide. Experiments were conducted 1–4 times, depending on the peptide.
doi:10.1371/journal.pone.0145629.g003
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Virus clearance in influenza infected mice immunized with double
restricted peptides
In spite of the apparent lack of immune reactivity against the four HLA-A02:01/
HLA-DRB101:01 binding immunogenic peptides in influenza challenged mice, we speculated
if T cells from immunized mice with specificity for the double restricted peptides (Figs 1 and
2), might still be capable of killing directly infected cells and thereby lower the virus titre. Thus,
groups of 3–6 transgenic mice were immunized three times with one or a combination of PA
(282–290, PA(282–292), PB1(410–418) and PB(410–419. Separate groups of mice were immu-
nized with the HLA-A02:01 binding M(58–66) peptide [21] and groups of mice were left
unimmunized or treated with CAF09 and Tris buffer. One week after the last immunization,
mice were challenged i.n. with 4.0, 0.4 and 0.04 LD50 of influenza A and 5 days later, influenza
M gene expression in lungs was measured by Q-PCR. Fig 4 shows that mice immunized with
the M(58–66) peptide and challenged with influenza A at 4.0 and 0.4 LD50 showed reduced
virus load, whereas immunization with the PA and PB1 peptides did not show any reduction
in virus load irrespectively of the influenza dose used for challenge.
Discussion
We have previously identified CD8 and CD4 T cell reactivity towards HLA class I and class II
double binding immunogenic 9mer influenza A-derived peptides in the peripheral blood of
healthy adult blood donors. Double binding or double restricted peptides were present for all
Fig 4. No protection against influenza infection in mice immunized with the double restricted epitopes. HLA transgenic mice were immunized three
times every second week with CAF09 and different combinations of double restricted immunogenic peptides or the known HLA-A*02:01 epitope M(58–66)
(20nM). One week post last immunization, mice were intranasally challenged with 4 LD50 (A), 0.4 LD50 (B), or 0.04 LD50 (C) of influenza A. As control groups,
mice were either injected three times at two week intervals with CAF09 and Tris buffer (A and B) or were non-immunized (C) before influenza challenge.
Influenza M gene expression in the lungs was measured by Q-PCR. Dots show numbers of M gene copies in the lungs per mice and horizontal lines depict
means of 3–6 mice. Experiments were conducted once. Groups were tested using Mann-Whitney and ns = not significant compared to CAF09 + Tris (B) or
non-immunized (C). Groups in A could not be tested by Mann-Whitney due to n = 3 in each group. Experiments were conducted once. Groups were tested
using Mann-Whitney and ns = non significant compared to CAF09 + Tris (B) or non-immunized (C). Groups in A could not be tested by Mann-Whitney due to
n = 3 in each group.
doi:10.1371/journal.pone.0145629.g004
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the twelve HLA class I supertypes [5]. T cell reactivity against HLA class I/II double binding
immunogenic 9mer peptides was also observed in the peripheral blood of donors vaccinated
20–40 years previously against smallpox and/or tuberculosis [6,7] indicating that reactivity
against double binding infection- or vaccination-derived peptides reflects the presence of long
term T cell memory. Intuitively, a peptide derived from an infectious agent triggering both
HLA class I and class II restricted T cell responses against the same epitope might induce
higher levels of immune protection than any peptide separately triggering a HLA class I or a
class II restricted response, respectively [8]. To further address this hypothesis, we here focused
on influenza A-derived peptides predicted in silico to bind to both HLA-A02:01 and
HLA-DRB101:01 molecules. After peptide synthesis, their binding to HLA-A02:01 and
HLA-DRB101:01 molecules was measured in a biochemical assay system [17]. The overall
agreement between the predicted and measured binding values of the 19 synthesized peptides
was high (see Table 1). The peptides were then tested for immunogenicity in HLA-A02:01/
HLA- DRB101:01 transgenic mice. Of the eight peptides measured to bind to both
HLA-A02:01/HLA-DRB101:01, four peptides showed HLA class I/class II double restricted
responses and the HLA class II restricted responses represented in particular Th2 (IL-4) reac-
tivity. These four peptides included two 9mer epitopes and their two extended versions, elon-
gated with either one or two amino acids. Ten peptides binding to HLA-A02:01 showed
HLA-A02:01 restricted responses whereas eight peptides, in spite of high HLA-A02:01 bind-
ing affinities, were not immunogenic in these experiments. We had expected to find that
splenic T cells frommice, challenged with Influenza A/Puerto Rico/8/34, would display reactiv-
ity towards at least some of the 18 assayed peptides and in particular the four immunogenic,
double restricted peptides. However, reactivity was only observed against the influenza matrix
M(58–66) peptide, the resulting CTL response known to be detectable in most HLA-A02:01
influenza experienced subjects [17]. Nonetheless, the present results agree quite well with pre-
vious data [5,7,22] in which only 5–10% of more than 600 9mer peptides derived from influ-
enza A virus, small pox virus, or mycobacterium tuberculosis were recognized by peripheral
blood T cells of immune donors, although these peptides were predicted and measured bio-
chemically for binding at high affinities to one or more of the twelve HLA class I supertypes
[4,5,7,22].The reason for low numbers of immunogenic or immune dominant peptides in a
given antigenic molecule is probably caused by limitations in the CD8 T cell repertoire as well
as inefficient antigen processing which, according to previous studies, appears to reduce the
number of immunogenic peptide epitopes within a given antigenic molecule by more than 90%
[23]. Also, throughout evolution, influenza A virus might, in a process of host adaption, have
been able to eliminate strong immunogenic peptides from their genome including double
HLA-I/II binding peptides. In addition, in naïve HLA-A02:01/HLA-DRB101:01 transgenic
mice, CD8 T cells represent only 2–3% of the peripheral T cell pool [24] and might therefore
reduce the overall CD8 T cell repertoire in these mice.
Unlike in the afferent arm of the immune system, peptide specific effector CD8 T cells
(CTL) need to recognize only a few MHC/peptide complexes to become activated and kill [25].
Thus, although splenic T cells from influenza challenged mice did not recognize the HLA dou-
ble binding peptides, or any of the other 19 HLA binding peptides of this study, predicted to be
single or double restricted, we speculated that directly influenza infected target cells might pro-
cess peptides at a level high enough to trigger low numbers of vaccine-induced CTLs not
detectable in influenza challenged mice by using the ELISpot system. To test this possibility,
peptide vaccinated and naive mice were challenged i.n. with titrated numbers of the Puerto
Rico/8/34 influenza strain A. We determined influenza matrix gene expression of virus infected
lungs using Q-PCR, and observed a decline in lung virus titres of influenza challenged mice
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vaccinated with the known HLA-A02:01 binding immunogenic M(58–66) peptide [21], but
no effect in mice immunized with a mixture of the four HLA double binding peptides.
A case for T cell epitope-based anti-influenza A vaccine
The primary port of entry of the influenza virus is the mucosa of the respiratory tract. The
adaptive immune system can provide immune protection against such mucosal pathogens
through secretory IgA and IgM immunoglobulins. These can effectively prevent the virus from
infecting its target cells, and the influenza viruses constantly go through antigenic changes to
escape such neutralizing immunoglobulins. Thus, although a vaccine strategy aimed at generat-
ing humoral immunity can be very effective, it may not be possible to pursue it before the exact
target is known.
Another arm of the adaptive immune system, that of HLA class I restricted, CD8 positive,
cytotoxic T cells (CTL), specifically survey the internal metabolism of our cells and detect intra-
cellular pathogens such as viruses Although this does not prevent the influenza virus from
infecting the mucosal target cells, it does allow for a cytotoxic immune response, which can
abort the transmission of infectious influenza virus from one host cell to the next thereby aid-
ing in the recovery from the infection. The presence of HLA class I and II restricted epitope by
the same antigenic peptide may add on additional anti-viral immunity by stimulating cross-
protective IL-4-stimulated humoral responses and provide immunological memory. Thus
combining bioinformatics, biochemistry, immunization technology and in vivomodel systems
might lead to generation of peptide-based vaccines capable of inducing cellular immunity
towards upcoming influenza A infections.
In conclusion, HLA class I and II double binding small immunogenic peptides exist. By
immunization, they simultaneously stimulate both HLA-I and–II restricted immune responses
against the same peptide epitope. Thus double restricted peptides could be new candidates for
peptide- based vaccines.
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